GlassScriptPhysician profile
Farnoosh Karimi
NPI 1073122602
$1,107.83
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $872 · 2022: $236.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $173.62 | 2021-2022 | |
| Daiichi Sankyo INC. | $170.61 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $138.19 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $93.29 | 2021-2022 | |
| Amarin Pharma, INC. | $92.91 | 2021 | |
| Lilly USA, LLC | $76.38 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $55.31 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $53.84 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $51.68 | 2022 | |
| Abbvie INC. | $38.37 | 2021-2022 | |
| Amgen INC. | $37.54 | 2021 | |
| Glaxosmithkline, LLC. | $25.64 | 2021-2022 | |
| Eisai INC. | $25.38 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.58 | 2021 | |
| Virtus Pharmaceuticals LLC | $20.45 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $17.05 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.99 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farnoosh Karimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.